Adverse Events (AE) and Laboratory Changes in a Real-World Population of Hepatitis C Virus (HCV)-Infected Patients With Chronic Kidney Disease (CKD) Treated With Sofosbuvir (SOF)-Based Therapy
| Autor: | Guillermo Ortiz, Nneka N. Ufere, Meghan E. Sise, Raymond T. Chung, Elke S. Backman, Gregory L. Hundemer |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Simeprevir
medicine.medical_specialty Sofosbuvir Bilirubin business.industry Hepatitis C virus medicine.disease_cause medicine.disease Virology Gastroenterology Regimen chemistry.chemical_compound Infectious Diseases Oncology chemistry Internal medicine medicine Hemoglobin Adverse effect business medicine.drug Kidney disease |
| Zdroj: | Open Forum Infectious Diseases. 2 |
| ISSN: | 2328-8957 |
| DOI: | 10.1093/ofid/ofv133.744 |
| Popis: | Results: Median age was 61 ± 8 years, 60% were white, 45% were transplant recipients, and 7% were HIV coinfected. At baseline, 41 (57%) had stage 3 CKD, and 31 (43%) had stage 1-2 CKD. RBVcontaining regimens were used in 26 (36%) of patients, 36 (50%) received SOF & simeprevir. Transient creatinine rise ≥ 0.3mg/dL during treatment was noted in 16 (22%) patients but on-treatment average eGFR did not differ significantly from baseline [mean (95% CI): 57mL/min (52-62) vs 58mL/min (53-63) respectively, P=0.26]. 55 (76%) patients experienced an adverse effects (AE) with 5 patients discontinuing due to AEs (Table 1). The sustained viral response rate (SVR12) was 77%. Change in hemoglobin at 8 weeks was greater in patients receiving RBV compared to those on a RBV-free regimen [median (Q1,Q3): -1.8g/dL (-3.6,-1.0) vs. -0.4g/dL (-1.4, 0.1), respectively; p=0.005]. Mean total bilirubin increased by 0.52mg/dL (p=0.01) from baseline to week 4 but post-treatment week 4 levels were on average 0.19mg/dL below baseline (p=0.015). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|